Connect with us

Stocks

Most Interesting Assets on the U.S. Stock Market

Published

on

By Dmitriy Gurkovskiy, Chief Analyst at RoboMarkets

This review comprises the stocks with the highest yield over the last 30 days.

 

STAAR Surgical Company (STAA)

STAAR Surgical Company was founded back in 1982. With its subsidiary companies, it develops, produces, and sells implantable ophtalmic lenses and systems for their implementation. Implantable lenses is a radical approach to treating such common vision disorders as myopia, long sight, astigmatism, and presbyopia. The company sells its products directly through its representatives in the UK, Germany, Spain, Canada, Singapore, the US, and Japan, and in 75 countries more through its independent resellers.

Among STAAR’s subsidiaries, one can name Domilens Vertrieb fuer medizinische Produkte GmbH, STAAR Japan Inc, and STAAR Surgical AG. The company falls into Healthcare (Medical Instruments & Supplies) sector.

Over the last month, STAAR shares have grown by 70.36%. Such a growth was caused by the Q1 earnings report that showed so good result that the profit forecast drastically increased for the whole 2018, namely, from 2% all the way to 20%! This is also because of the good results in the Asian market.

In Q1 2018, STAAR net profit amounted to 0.6M USD, or $0.01 per share, against -$2.2M or $0.05 per share in Q1 last year. The biggest profit share was brought by Visian ICL, the product the company expects even more from moving forward. This product is very much like a regular contact lens implemented into an eye. This allows people with myopia or far sight to stop using contact lenses, which solves the so-called ‘dry eye’ issue. Implantable lens implementation is done by a physician, but costs far less than a regular eyesight recovery operation.

In 2018, STAAR is going to continue investing into Visian ICL clinical trials, which means more profit and good earnings reports in the future.

Technically, there is an ascending trend forming, with the price being above the 200-day SMA. The key resistance at $17 had been active since December but finally got broken out, while the immediate support is now at $22. There are no fresh resistance levels on the chart yet, as the price is at its highs since the stock’s inception. Short float is very low, at 2.36%, while the investment funds own over 79.9% of the shares and have not sold them recently.

 

PolarityTE, Inс. (COOL)

PolarityTE, Inс. is a biotech company founded back in 1998, developing regenerative tissue and biomaterials for medical purposes. PolarityTE results in regeneration are really unique.

PolarityTE technology is based on the patient’s healthy tissue which then creates a self-spreading product designed to strengthen and stimulating patient’s cells for regeneration purposes. Instead of making synthetic or third-party materials, PolarityTE uses patient’s tissue, which helps develop the regeneration process much better. The innovative PolarityTE method enables speeding up the recovery process.

Among the company subsidiaries, one can name Jesse M. Sutton Foundation, Majesco Entertainment, Zift Interactive LLC, and Paradigm Shift Universal, Inc. The company falls into Healthcare/Biotechnology sector.

Over the last month, PolarityTE share price went up by 51.93%, mainly because of its major product called SkinTE. Those who already tried it are very happy about it, which is an additional marketing stimulus for the company.

Here’s some feedback of one of the patients: ‘I damaged my skin badly in a motorbike accident a few years ago. The wounds were so serious that no medical care could help, as the skin just would not recover. Finally, they had to transplant the skin, but this lasted for a few months, while the wounds were bleeping, and when they took off the bandage, around 50% of the transplanted skin was left there. After that, I decided to use SkinTE, and just in a few weeks the skin fully recovered, including even the hair coat.’

More and more reviews like this one are coming in everyday. SkinTE helps recover skin after fire burns, chemical burns, lacerations, and other skin damages. The recovery process is much more speedy than regular one, and is very convenient. The company is using this good situation to find resellers in the East Coast in order to boost sales.

Until April, the stock was downtrending, but SkinTE news was a real game changer for PolarityTE, Inc, as it broke out the 200-day SMA, signaling for a newborn ascending trend.

Meanwhile, the investment funds’ PolarityTE buys grew by 14.23%, while the board members still have around 45% of shares and have not sold them recently.

Short float at 18.78% is an additional stimulus for the stock growth, as the bears have to close their positions, thus pushing the price higher.

The closest support that may be reached by a pullback is at $22, while the closest support is at around $30.

 

IntriCon Corporation (IIN)

IntriCon Corporation (IIN) was founded back in 1930, and is currently developing, producing and selling software for medical appliances, hearing kits, and audio communication devices. IntriCon also offers earsets for law enforcement institutions, aviation, and military, as well as small versions for musicians and security guards. IntriCon Corporation was formerly known as Selas Corporation of America.

Among the company subsidiaries, one can name EarVenture LLC, Hearing Help Express, Inc., IntriCon Datrix Corporation, IntriCon GmbH, IntriCon PTE LTD, IntriCon Tibbetts Corp, PC Werth Ltd, Resistance Technology, Inc., RTI Electronics, Inc., and RTI Technologies PTE LTD. The company stock falls into Industrial Goods (Industrial Electrical Equipment) category.

Over the Last month, IntriCon increased the investor profit by 50.76%, mostly because of the Q1 earnings report that exceeded expectations. The company’s net profit reached $25.4M, which is 19.6% bigger than last year (around $21.2M). The shareholders’ net profit in Q1 2018 was $769,000, or $0.10 per share, compared to -$270,000 or -$0.04 per share in Q1 2017.

This year, the company focuses on the hearing aid and continuous sugar monitoring devices. Both products are going to be very much in demand, as the ‘baby boomers’ are getting old but are still used to the gadgets that make their lives more comfortable.

Diabetes is one of the most serious problems in the US, as more and more elderly Americans get this diagnosis. In case such patients do not stick to the diet and workout plans, their health becomes worth further. Such people have to always control their sugar level, while the devices used for that purpose used to be large and difficult to use. IntriCon and Medtronic PLC (MDT) succeeded in making them more compact and easy to use, allowing the patients to monitor their sugar level without any major issues.

Medtronic PLC controls over 81% of the sugar level measuring device market, so IncriCon partnering with them allows the company to boost their sales even further. As of now, InctriCon is going to rent additional 37 000 square feet of facilities to boost the production.

The investor sentiment can be easily confirmed by tech analysis figures. The price is above the 200-day SMA, which means there’s an uptrend in place. There are no resistance levels near the price, as the company is making its record highs.

The investors are a bit worried about the large volumes as the price is going up, so a large correction may occur this week, with the price reaching $19 or even $17.

Meanwhile, the short float is just 2.44%, and the investment fund share is 2.27%.

Disclaimer

Any forecasts contained herein are based on the authors’ particular opinion. This analysis may not be treated as trading advice. RoboForex bears no responsibility for trading results based on trading recommendations and reviews contained herein.

Featured image courtesy of Shutterstock. 

Important: Never invest (trade with) money you can't afford to comfortably lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here. Trade recommendations and analysis are written by our analysts which might have different opinions. Read my 6 Golden Steps to Financial Freedom here. Best regards, Jonas Borchgrevink.

Rate this post:

Important for improving the service. Please add a comment in the comment field below explaining what you rated and why you gave it that rate. Failed Trade Recommendations should not be rated as that is considered a failure either way.
0 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 5 (0 votes, average: 0.00 out of 5)
You need to be a registered member to rate this.
Loading...

4.6 stars on average, based on 23 rated postsHaving majored in both Social Psychology and Economics, I went on to continue my education in post graduate. Later I worked as a team lead of a tech and fundamental analysis lab in the Applied System Analysis Research Institute. This helped me to acquire all necessary skills and experience to become a successful trader and analyst, as well as a portfolio manager in an investment company. I'm a pro in the financial field and the author of articles for various international media. I also hold the position of Chief Analyst at RoboMarkets.




Feedback or Requests?

Click to comment

You must be logged in to post a comment Login

Leave a Reply

Analysis

Johnson & Johnson: Not the One to Go Down?

Published

on

By Dmitriy Gurkovskiy, Chief Analyst at RoboMarkets

With the new season ahead, investors’ fears are fading out. The market is trying to find its bottom and bounce off it, if somewhat timidly. Few investors were bold enough to get into risks before the New Year, most preferred to lock in their hard-earned profits, which subsequently led to the overall downtrend.

There were some other reasons, too, though. The quarterly reports went better and better, which first was a good signal for keeping stocks within the portfolios. However, in Q4 2018, some companies were barely able to meet expectations, while others set their expectations way lower for the future periods. Facebook, for instance, was unable to meet expectations for two times in a row, despite the profits hitting the record highs. Meanwhile, Apple met expectations, but iPhone sales went significantly lower in Q4. General Motors revenues were completely based on automobile prices, while sales plunging, too. Some of these issues are due to the Sino-US trade war, but even without it the market would have gone down anyway, if at some higher price levels. Every company has its limit, and once it’s reached, a correction is inevitable. On the other hand, every company makes progress through innovative ideas, and when it manages to create a new unique product or service, its price goes drastically up.

Speaking of Facebook, Zuckerberg’s company multiplied its revenues more than threefold, from $4B in 2015, to $14B. Alphabet, the parent company of Google, succeeded in growing its revenues from $18B to $34B. Apple earnings are not growing as fast as Google’s, being very choppy, and it looks like the tech giant hit its iPhone sales limit. In 2015, Apple earned $58B, and had only 13% more by late 2018. The management finally opted for not disclosing the sales data, which had a very negative effect.

These figures do not look that impressive at first sight, and one may even think they could be way bigger. On the other hand, however, just think of it: a single US-based company earnings are bigger than the entire GDP in Bulgaria, Luxemburg, or Croatia.

Meanwhile, crude oil lost over 40% over the last three months. The stock indices, led by the S&P 500, followed in the same manner they had followed the rising crude price in 2017. This makes one think the indices will start rising as soon as crude finds support and bounces. Cheap crude is bad for exporters, while for other countries, it is a great tool, as producing nearly each and every product (or at least its packing or shipping) requires oil.

Whether crude has already found its support, or it will continue falling, remains to be seen. Investors are now interested in the crude and indices, but not that much so as to make the things really optimistic and push the prices higher. A fall is quite possible anyway, and the currently open long positions are under considerable risk.

When indices are going down, fear in the markets is so great that people sell even the stocks of the companies that are doing rather good. In order to provide the appropriate reasoning, the analysts usually remind the markets of a piece of negative news, even long-gone and forgotten. The stock then goes well bellow the oversold territory, just to give the investors a better opportunity to buy it later.

One of such oversold companies, with the stock price going down with no particular reason, is Jonson & Jonson (NYSE: JNJ), which includes over 250 child companies throughout the world. Johnson & Johnson produces medicines, hygienic products, and medical equipment. It was founded in 1887 by three brothers: Robert, James, and Edward Johnson.

Financially, the company is very much stable, and its earnings are rising steadily.

The chart below shows the earnings always beat expectations in 2017, which allowed the stock price to hit the historical high.

The price chart shows a very clear uptrend, with the price always being above the 200-day SMA, the latter acting as a support. In mid 2018, however, the stock lost as much as 20%, in a very short time frame. The earnings report was good, but the overall outlook was spoiled by the court decision, upon which J&J was fined at $4.70B.

The complainants affirmed that the baby dust produced by J&J contained asbestos, which may cause ovarian cancer. The similar trials had already been held in 2007, when the company first had to pay $417M to the injured US citizen, but later the decision was revoked, as no proofs for the event of crime were found. At that time, the market barely reacted at that legal action, probably because the amount was not that high.

It is quite high this time, though, so the news could not have gone unnoticed anyways. It was already priced into the stock in July 2018, however, as this is when the court took this decision. Ever since, the price went up again, and good earning reports pushed the price to the new all-time highs.

The ascending trend could well have continued, had it not been for the indices. Those fell considerably, and Johnson&Johnson was unable to stand ground. In order to justify the fall, the company remembered the legal action, which only made this fall steeper.

The situation was so grave that J&J had to announce it was going to buy the shares out for $5B, with the management considering the low price as an attractive investment opportunity.

Meanwhile, a recently concluded research, that had been in progress for decades, showed that American women living in the rural areas suffer from ovary cancer more often than those living in cities, although it is in cities when you find asbestos far more often. This means the connection between asbestos and cancer, if it exists, is not obvious.

Another research, however, highlighted that using amphibole asbestos led to the growing number of cases of occupational diseases. Amphibole asbestos is nowadays forbidden around the world.

The information on this research came roughly at the same time as the court decision on J&J. Nobody wanted to consider it all in detail, and which kind of asbestos it was about.

The whole story was so much overblown that each and every US citizen can now claim compensation from Johnson&Johnson. If this goes around the thousand of cities and towns J&J operates in, it could well lead to bankruptcy.

How you want to act in this market situation, remains up to you. You’ve got the crazy tumult on the one hand, and the logic on the other. The logic says the scandal is pretty much overblown, and those who initiated it are sure to lose in the end. Who is going to win then? Those who will control their emotions and take a weighted decision on buying the underpriced stock. This is because, now, the stock is far more likely to rise than to fall, both according to the overall situation and the fact that the trials started as early as in summer 2018.

Disclaimer

Any predictions contained herein are based on the authors’ particular opinion. This analysis shall not be treated as trading advice. RoboMarkets shall not be held Company for the results of the trades arising from relying upon trading recommendations and reviews contained herein.

Important: Never invest (trade with) money you can't afford to comfortably lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here. Trade recommendations and analysis are written by our analysts which might have different opinions. Read my 6 Golden Steps to Financial Freedom here. Best regards, Jonas Borchgrevink.

Rate this post:

Important for improving the service. Please add a comment in the comment field below explaining what you rated and why you gave it that rate. Failed Trade Recommendations should not be rated as that is considered a failure either way.
0 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 5 (0 votes, average: 0.00 out of 5)
You need to be a registered member to rate this.
Loading...

4.6 stars on average, based on 23 rated postsHaving majored in both Social Psychology and Economics, I went on to continue my education in post graduate. Later I worked as a team lead of a tech and fundamental analysis lab in the Applied System Analysis Research Institute. This helped me to acquire all necessary skills and experience to become a successful trader and analyst, as well as a portfolio manager in an investment company. I'm a pro in the financial field and the author of articles for various international media. I also hold the position of Chief Analyst at RoboMarkets.




Feedback or Requests?

Continue Reading

Analysis

Apple vs Qualcomm: We’ve Got No Winner Here

Published

on

By Dmitriy Gurkovskiy, Chief Analyst at RoboMarkets

On Dec 10, it became known that the Intermediate People’s Court of Fuzhou acknowledged that Apple (NASDAQ: AAPL) violated two patents of Qualcomm (NASDAQ: QCOM), a chip manufacturer. The patents are regarding photo editing and managing apps with a touchscreen. The court’s decision was banning Apple from importing and selling iPhone 6S, 6S Plus, 7, 7 Plus, 8, 8 Plus, and iPhone X in China. This does not affect iPhones released in 2018, i.e. iPhone XS, XS Max, and XR, though. Curiously, the decision was taken on Nov 30, but the media covered it only on Dec 10.

Over the trading week between Dec 3 and Dec 7, the Apple stock fell from $180 to $168, while as soon as the information became available to the public, the stock went slightly up. although having lost around 2% in the pre-market. Thus, earning by selling this bad news proved impossible.

The stock, however, was unable to recover till $180, still falling now and being in the negative with the overall stock index drop. Did Qualcomm strike Apple so much that investors decided to abandon the stock?

If it were the case, however, and Apple lost so much each time there was legal action against the company, we would not witness a steady uptrend around the last ten years. This is even not the first time Qualcomm files an action against Apple; besides, previously, Apple had to face multiple trials against Samsung, also regarding the patent rights. Currently, Apple is busy patenting everything it can, so that next time it may be the first to file an action.

Meanwhile, despite the court’s decision coming into effect since early December, it is still de-facto ignored, with iPhones still being sold in Chinese stores.

Qualcomm sent some proof to the court and is now demanding the iPhones may be no longer sold, while Apple affirms the decision covered just the previous iOS versions, while iOS12 does not violate any Qualcomm patents. Apple even updated their phone’s firmware last week in order to resolve this issue, but the court did not acknowledge it as a solution. Apple is of course going to appeal the court’s decision now while updating the firmware was more like an attempt to buy some more time.

Qualcomm is sometimes considered as a mobile platform monopolist, and this is confirmed with some anti-monopoly authorities’ decisions in the EU, Taiwan, and South Korea. Qualcomm competition was not at all fair, as the company offered Apple good discounts in exchange for the tech giant’s not purchasing chips from other manufacturers.

In Jan 2017, however, Apple filed an action against Qualcomm worth $1B in the US, as the latter did not return them the cash for those discounts.

Now, it looks like Qualcomm is attempting to take revenge. Besides filing an action in Fuzhou, the chip manufacturer also filed a complaint to the Munich court, which also took Qualcomm’s side on Dec 20. This lead to banning iPhone 7&8 from selling in Germany as well.

However, in order to drive the decision into effect, Qualcomm has to deposit EUR688M on escrow, while Apple still has the right to appeal. Qualcomm still has a potential to deteriorate Apple’s stats for the next few quarters. The Q4 report already confirmed that 1M less iPhones were sold than a quarter before, and this might be just the beginning. Once the report came out, the stock started making new lows, with the court decisions only adding to the negative side.

This looks a bit like the Facebook story, when  investors pushed the stock down just because the number of new users started going down, even while the earning reports were fine, with the 2015 data leakage scandal adding the fuel to the fire.

Qualcomm’s strike against Apple is very painful for the company. The tech giant might have just paid compensation, and this would have been the end. Now, it is becoming quite serious. If Apple is unable to demonstrate the higher than expected sales rise, which has been a common thing over the last time, this may mean the company’s fading out, and the investors will start trying to find a better option. For Qualcomm, on the other hand, this would not mean a 100% win. Over the last three years, the company’s earnings were going down. They had to pay high fines, and the investors are not very interested in buying their shares, with no uptrend emerging.

Their most important rival, Intel (NASDAQ: INTC), has meanwhile beaten them in terms of earnings.

Once Qualcomm stopped being able to demonstrate rising revenue, the stock started failing immediately. It reached its high at a bit above $80 in 2014 and has not been able to rise higher yet.

It is currently trading in a tight channel without majorly going up or down, allowing short term traders to capitalize on random choppy moves, with over 30% profit.

Meanwhile, Apple reached its technical top in September, trading at around $230. It tried to go even further in October, but failed, and then the price consolidated, pushed down to the nearest lows. The consolidation was most likely due to the investors expecting the Q4 report. Right before it came out, Apple formed a head and shoulders pattern, which might signal a reversal.

The neckline of the pattern got broken out right at the report, with bad earnings and negative court decisions pushing the price lower.

Where the absolute low lies, is still unknown. The 200-day SMA, however, may be a good reference option, as the price may well bounce off it. Still, with all major US indices going down, Apple price may sink lower, too, forming then a brand new support. This negative trend may only be stopped by a good earnings report with nice sales data.

When it rains, it pours. With the overall indices fall, bad sales, and negative court decisions, Apple is very much under pressure. Note that the moment when the market crowd stops buying and starts selling in panic is usually very unexpected. Those who still believe in the US tech giant should have patience and wait. The markets may calm down after the holidays, and the stock may again prove to be a good long term investment vehicle.

Disclaimer

Any predictions contained herein are based on the authors’ particular opinion. This analysis shall not be treated as trading advice. RoboMarkets shall not be held Company for the results of the trades arising from relying upon trading recommendations and reviews contained herein.

Important: Never invest (trade with) money you can't afford to comfortably lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here. Trade recommendations and analysis are written by our analysts which might have different opinions. Read my 6 Golden Steps to Financial Freedom here. Best regards, Jonas Borchgrevink.

Rate this post:

Important for improving the service. Please add a comment in the comment field below explaining what you rated and why you gave it that rate. Failed Trade Recommendations should not be rated as that is considered a failure either way.
0 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 5 (0 votes, average: 0.00 out of 5)
You need to be a registered member to rate this.
Loading...

4.6 stars on average, based on 23 rated postsHaving majored in both Social Psychology and Economics, I went on to continue my education in post graduate. Later I worked as a team lead of a tech and fundamental analysis lab in the Applied System Analysis Research Institute. This helped me to acquire all necessary skills and experience to become a successful trader and analyst, as well as a portfolio manager in an investment company. I'm a pro in the financial field and the author of articles for various international media. I also hold the position of Chief Analyst at RoboMarkets.




Feedback or Requests?

Continue Reading

Analysis

2018 Top Stocks

Published

on

By Dmitriy Gurkovskiy, Chief Analyst at RoboMarkets

As 2018 is heading towards its end, one can say it was a harsh year for stock investors. The major US indices are on track for yearly losses, while over 2017 they were 30% up. Let us see, however, which companies were the biggest gainers in 2018, with the largest yield, excluding the dividends.

Traditionally, biotech companies are leaders, with thousands of percent YoY growth; however, one would surely rather buy shares of a famous company with a solid track record than make wild guesses whether a new biotech starlet will rise from a few cents to a few bucks or not. The cannabis-related companies were among the leaders this year, too, with their yield growing by 1,000% or even more right after IPO’s; Tilray (NASDAQ: TLRY), for instance, added 1,500% just in two months. This was more like of a bubble, however, that finally did explode, with the price going back to its normal levels.

Apart from the unknown and small companies, the top gainer is Twilio Inc. (NYSE: TWLO), which rose by impressive 306% over 2018.

Founded in 2008 and headquartered in San Francisco, CA, Twilio is a tech company that develops online communication software. It successfully ran its IPO on NASDAQ in 2016. Since then, its earnings have always beaten the analysts’ expectations, reaching a total of $169M, from initial $64M.

MongoDB (NASDAQ: MDB), another tech company, is second. Mongo was founded in 2008 and is headquartered in New York City.

In 2017, it ran its IPO, but it was not until February 2018 that its share price suddenly went massively higher – the yield rise totaling 201%. The earnings report released in early 2018 attracted a lot of new investors, as the company beat many analysts’ expectations.

Tabula Rasa HealthCare Inc (Nasdaq: TRHC), yet another tech company, takes third place. This one was founded in 2009 and is headquartered in Moorestown, NJ. The company operates only in the US, developing various healthcare technologies. Over 2018, Tabula Rasa HealthCare stock price rose 169%.

While some tech companies rising nicely, the whole sector has been desperately down.

Social media giant Twitter (NYSE: TWTR) went up by 65%, but at the same time, Facebook (NASDAQ: FB) lost 18%, under pressure coming from both privacy scandals and the shortage of new users.

The Dow Jones Industrial Average (INDEXDJX: DJI) failed to rise by even 1% in 2018, losing instead around 0.91%. However, some companies included into this index managed to rise by dozens of percent.

Speaking about the biggest losers, Goldman Sachs (NYSE: GS) takes the ‘lead’ here, with a 31% fall over 2018. The bank is followed by IBM (NYSE: IBM) and Caterpillar (NYSE: CAT), that also failed to rise and plunged by 21.30% and 20.00%, respectively.

Just like the DJIA, the S&P 500 has been down so far, losing 1.68%. Still, some companies included into this index managed to rise by as much as 60%.

The worst S&P performer was General Electric (NYSE: GE), which is now attempting to reduce costs and stay in the market; it looks like investors do not trust this company enough, though, that’s why General Electric has lost almost 60% so far this year.

The best performer among indices in 2018 is Nasdaq 100, which added nearly 4%. Among the leading companies in this index, one should note Amazon, Illumina, Netflix, O’reilly, Twenty-First Century Fox, and Workday, all rising by over 40% YoY.

Meanwhile, the Chinese JD.com Inc (NASDAQ: JD) lost 47%, mostly because of the Sino-US trade war. Besides, its CEO, Liu Qiangdong, was arrested being accused of sexual harassment, which added pressure to the company and reduced the trust among the investors. In case Liu is sent to jail, the risks for JD.com will increase drastically.

Disclaimer

Any predictions contained herein are based on the authors’ particular opinion. This analysis shall not be treated as trading advice. RoboForex shall not be held liable for the results of the trades arising from relying upon trading recommendations and reviews contained herein.

Important: Never invest (trade with) money you can't afford to comfortably lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here. Trade recommendations and analysis are written by our analysts which might have different opinions. Read my 6 Golden Steps to Financial Freedom here. Best regards, Jonas Borchgrevink.

Rate this post:

Important for improving the service. Please add a comment in the comment field below explaining what you rated and why you gave it that rate. Failed Trade Recommendations should not be rated as that is considered a failure either way.
1 vote, average: 5.00 out of 51 vote, average: 5.00 out of 51 vote, average: 5.00 out of 51 vote, average: 5.00 out of 51 vote, average: 5.00 out of 5 (1 votes, average: 5.00 out of 5)
You need to be a registered member to rate this.
Loading...

4.6 stars on average, based on 23 rated postsHaving majored in both Social Psychology and Economics, I went on to continue my education in post graduate. Later I worked as a team lead of a tech and fundamental analysis lab in the Applied System Analysis Research Institute. This helped me to acquire all necessary skills and experience to become a successful trader and analyst, as well as a portfolio manager in an investment company. I'm a pro in the financial field and the author of articles for various international media. I also hold the position of Chief Analyst at RoboMarkets.




Feedback or Requests?

Continue Reading

Recent Posts

A part of CCN

Hacked.com is Neutral and Unbiased

Hacked.com and its team members have pledged to reject any form of advertisement or sponsorships from 3rd parties. We will always be neutral and we strive towards a fully unbiased view on all topics. Whenever an author has a conflicting interest, that should be clearly stated in the post itself with a disclaimer. If you suspect that one of our team members are biased, please notify me immediately at jonas.borchgrevink(at)hacked.com.

Trending